Cerevel is a Massachusetts-based biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of neuroscience diseases.
We're tracking Cerevel Therapeutics's market expansion
How Cerevel Therapeutics's international expansion compares to its competitors
Cerevel TherapeuticsYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Cerevel TherapeuticsYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
AbbVie acquired Cerevel Therapeutics for $8.7 billion to expand its neurology portfolio, integrating innovative CNS therapies including Tavapadon for Parkinson's disease and Emraclidine for schizophrenia.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Cerevel Therapeutics's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
